Neonatal Respiratory Distress Syndrome Treatment Market

Neonatal Respiratory Distress Syndrome Treatment Market (Therapy: Oxygen Therapy, Surfactant Therapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Outlook 2031

  • The industry was valued at US$ 780.1 Mn in 2022
  • It is projected to grow at a CAGR of 7.9% from 2023 to 2031 to reach more than US$ 1.6 Bn by the end of 2031

Analysts’ Viewpoint

The neonatal respiratory distress syndrome treatment market is expected to witness significant growth in the next few years owing to rise in incidence of premature births and technological advancement in neonatal care. Increase in birth rate, especially in developing countries, is further contributing to the neonatal respiratory distress syndrome treatment market development.

Key market contributors are investing in research and development to develop new and innovative treatments for NRDS, and grabbing incremental neonatal respiratory distress syndrome treatment business opportunities. Surfactant therapy, extracorporeal membrane oxygenation (ECMO), and high-frequency ventilation are some of the effective NRDS treatments gaining tremendous traction worldwide. However, lack of trained healthcare personnel and limited availability of specialized NRDS treatment centers are expected to hamper market statistics during the forecast period.

Neonatal Respiratory Distress Syndrome Treatment Market

Market Introduction

Neonatal respiratory distress syndrome (NRDS) is a condition that affects newborns, especially premature infants. It occurs when the newborn's lungs are not fully developed and are unable to produce enough surfactant ‒ a substance that helps keep the air sacs in the lungs open. Consequently, newborns experience difficulty in breathing. They may experience rapid, shallow breathing, and skin becomes bluish due to lack of oxygen.

Respiratory distress syndrome (RDS) is a serious condition that can lead to complications such as pneumonia, brain damage, and, in severe cases, death. Treatment for RDS typically involves providing the newborn with supplemental oxygen and, in some cases, mechanical ventilation to help the newborn breathe. In some cases, surfactant replacement therapy may be used to supplement the newborn's natural surfactant production. The treatment for NRDS typically involves, mechanical ventilation, surfactant replacement therapy, and supportive care.

Rise in Incidence of Premature Births

Premature birth is a major risk factor for neonatal respiratory distress syndrome, as premature infants are more likely to develop the condition due to their underdeveloped lungs.

Rise in number of premature births, globally, is contributing to the corresponding increase in the incidence of RDS, thereby driving the demand for neonatal respiratory distress syndrome treatment. This factor is likely to propel the future of neonatal respiratory distress syndrome treatment market during the forecast period.

According to the World Health Organization, approximately 15 million babies are born prematurely each year. Preterm birth affected approximately one out of every ten infants born in the U.S. in 2021. The rate of preterm birth increased by 4% in 2021, from 10.1% in 2020 to 10.5% in 2021.

Advances in Neonatal Care to Accelerate Market Dynamics

Advancements in neonatal care have been driving the growth of the neonatal respiratory distress syndrome (RDS) market. The survival rate of premature infants with RDS has increased due to improved diagnostic methods and treatments, which in turn is fueling the demand for neonatal care services.

Various leading companies play a key role in the development of new treatments and technologies to cure respiratory distress syndrome (RDS) in newborns. For instance, Smiths Medical is a medical device company that offers neonatal care products, including neonatal ventilators and respiratory support devices for RDS.

Babies have survived longer and with less lung damage since the introduction of volume-targeted ventilators. These babies require ventilator support for shorter periods of time and have a lower risk of developing pneumothorax. Volume-targeted ventilators aid in the maintenance of more stable carbon dioxide levels in blood and the reduction of brain ultrasound abnormalities. However, more research is needed to determine whether volume-targeted ventilators improve movement and intellect development in these babies.

Surfactant Therapy Proved to be Efficient in Managing NRDS

The surfactant therapy is one of the lucrative neonatal respiratory distress syndrome treatment market segments. It is expected to dominate the global market in the next few years.

Surfactant therapy is a treatment for neonatal respiratory distress syndrome (RDS) that involves the administration of artificial surfactants to premature infants with underdeveloped lungs. The surfactant is designed to mimic the natural surfactant that is produced by the lungs and helps keep the air sacs in the lungs open, reducing the risk of collapse, and ensuring adequate oxygenation.

Surfactant therapy is typically administered via a tube inserted into the baby's trachea. It has been shown to be effective in reducing the severity of RDS, reducing the need for mechanical ventilation, and improving survival rates among premature infants. Surfactant therapy is used in conjunction with oxygen therapy, and is only administered to infants who are not responding adequately to oxygen therapy alone.

Followed by surfactant therapy, the oxygen therapy segment accounted for major market share of the global neonatal RDS treatment market. Oxygen therapy is considered a major treatment for neonatal RDS and is widely used to provide adequate oxygenation to premature infants with underdeveloped lungs. Other treatments such as surfactant replacement therapy and mechanical ventilation are also available; however, oxygen therapy remains the most commonly used treatment for neonatal RDS.

Hospitals Provide Efficient Neonatal Intensive Care for Patients with RDS

According to the global neonatal respiratory distress syndrome treatment market analysis report, the hospitals segment is projected to account for major share of the global market during the forecast period. Hospitals are equipped with the necessary facilities, equipment, and trained medical staff to provide neonatal intensive care and treat premature infants with RDS.

The use of oxygen therapy, surfactant therapy, and mechanical ventilation for the treatment of neonatal RDS is typically performed in hospital settings, making hospitals the primary providers of neonatal RDS treatment. Additionally, numerous premature infants with RDS require hospitalization and ongoing medical care, further driving the demand for neonatal RDS treatment in hospital settings.

Regional Outlook of Neonatal Respiratory Distress Syndrome Treatment Industry

North America is likely to dominate the global neonatal respiratory distress syndrome treatment market during the forecast period. The neonatal respiratory distress syndrome treatment market size in the region is projected to increase in the near future, owing to the availability of advanced healthcare infrastructure, high incidence of premature births, and increased healthcare expenditure. Additionally, the presence of major players in the region along with rise in availability of innovative treatments for NRDS is also contributing to market expansion.

Additionally, the neonatal respiratory distress syndrome treatment market in Asia Pacific is expected to grow significantly in the next few years. This growth can be attributed to increase in birth rates, rise in awareness about NRDS treatment, and growth in the healthcare industry in the region. Additionally, the presence of developing countries in the region, such as India and China, with large populations and improving healthcare systems, is also expected to augment the neonatal respiratory distress syndrome treatment market value in the near future. However, limited access to advanced medical treatments and lower healthcare expenditure in some parts of the region may hinder market progress in the region.

Analysis of Key Players

Neonatal respiratory distress syndrome treatment market growth can be ascribed to the increase in adoption of innovative strategies by key market leaders. These market leaders are engaged in expansion of product portfolio and mergers & acquisitions to gain revenue benefits.

Companies including Medtronic, Drägerwerk AG & Co. KGaA, GE HealthCare, Koninklijke Philips N.V., Smiths Medical (ICU Medical, Inc.), Fisher & Paykel Healthcare Limited, IBIO, INC., Windtree Therapeutics Inc., Synthetic Biologics, and Synairgen are contributing to the major neonatal respiratory distress syndrome treatment market share during the forecast period.

Key Developments in Neonatal Respiratory Distress Syndrome Treatment Market

  • In September 2022, InnAccel Technologies and the Centre for Cellular and Molecular Platforms united with the SAMRIDH Healthcare Blended Finance Facility to offer respiratory support to newborns as well as the pediatric population in Assam, India. This support is based on an indigenous life-saving technology to shrink neonatal mortality due to respiratory distress syndrome (RDS) in the state.
  • In May 2021, Medtronic, a global company in medical technology, services, and solutions, launched the SonarMed Airway Monitoring System in the U.S. It is the first and only device of its kind that uses acoustic advanced technologies to check for endotracheal tube (ETT) obstruction and ascertain position in real-time, providing clinicians with vital data required to make more informed, life-saving decisions for their smallest patients.
  • In May 2019, SIME, a clinical AI company developing unique biological data to deliver life-saving solutions, announced the publication of its pivotal ‘Fast Assessment of Lung Maturity at Birth‘ study. The study validates the first application of the company’s patented AI Platform: a rapid point-of-care neonatal Lung Maturity Test (LMT).

The neonatal respiratory distress syndrome treatment industry report profiles key players based on parameters such as financial overview, company overview, business strategies, recent developments, business segments, and product portfolio.

Market Snapshot

Attribute

Detail

Market Size Value in 2022

US$ 780.1 Mn

Market Forecast Value in 2031

More than US$ 1.6 Bn

Growth Rate (CAGR)

7.9%

Forecast Period

2023–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Mn/Bn for Value

Market Analysis

It includes segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Therapy
    • Oxygen Therapy
      • Nasal Cannula
      • Continuous Positive Airway Pressure (CPAP)
      • Ventilator
    • Surfactant Therapy
    • Others
  • End-user
    • Hospitals
    • Sub-acute Facilities
    • Home Care
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Medtronic
  • Drägerwerk AG & Co. KGaA
  • GE HealthCare
  • Koninklijke Philips N.V.
  • Smiths Medical (ICU Medical, Inc.)
  • Fisher & Paykel Healthcare Limited
  • IBIO, INC.
  • Windtree Therapeutics Inc.
  • Synthetic Biologics
  • Synairgen
  • Other Prominent Players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global neonatal respiratory distress syndrome treatment market in 2022?

The global market was valued at US$ 780.1 Mn in 2022

How big will it be in 2031?

It is projected to reach more than US$ 1.6 Bn by 2031

What will be the CAGR during the forecast period (2023–2031)?

It is anticipated to grow at a CAGR of 7.9% from 2023 to 2031

Which is the prominent trend that affect industry growth?

Development of new and innovative treatments for NRDS, such as surfactant therapy, extracorporeal membrane oxygenation (ECMO), and high-frequency ventilation

Which region is anticipated to account for major share during the forecast period?

North America is projected to account for major market share during the forecast period

Who are the prominent players in the business?

Medtronic, Drägerwerk AG & Co. KGaA, GE HealthCare, Koninklijke Philips N.V., Smiths Medical (ICU Medical, Inc.), Fisher & Paykel Healthcare Limited, IBIO, INC., Windtree Therapeutics Inc., Synthetic Biologics, and Synairgen

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Neonatal Respiratory Distress Syndrome Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Technological Advancements

        5.2. Key Product/Brand Analysis

        5.3. Insights on Prevalence of Respiratory Distress Syndrome in Neonates

        5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

    6. Global Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast, by Therapy

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Therapy, 2017–2031

            6.3.1. Oxygen Therapy

                6.3.1.1. Nasal Cannula

                6.3.1.2. Continuous Positive Airway Pressure (CPAP)

                6.3.1.3. Ventilator

            6.3.2. Surfactant Therapy

            6.3.3. Others

        6.4. Market Attractiveness Analysis, by Therapy

    7. Global Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast, by End-user

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by End-user, 2017–2031

            7.3.1. Hospitals

            7.3.2. Sub-acute Facilities

            7.3.3. Home Care

            7.3.4. Others

        7.4. Market Attractiveness Analysis, by End-user

    8. Global Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America (LATAM)

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Therapy, 2017–2031

            9.2.1. Oxygen Therapy

                9.2.1.1. Nasal Cannula

                9.2.1.2. Continuous Positive Airway Pressure (CPAP)

                9.2.1.3. Ventilator

            9.2.2. Surfactant Therapy

            9.2.3. Others

        9.3. Market Value Forecast, by End-user, 2017–2031

            9.3.1. Hospitals

            9.3.2. Sub-acute Facilities

            9.3.3. Home Care

            9.3.4. Others

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Therapy

            9.5.2. By End-user

            9.5.3. By Country

    10. Europe Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Therapy, 2017–2031

            10.2.1. Oxygen Therapy

                10.2.1.1. Nasal Cannula

                10.2.1.2. Continuous Positive Airway Pressure (CPAP)

                10.2.1.3. Ventilator

            10.2.2. Surfactant Therapy

            10.2.3. Others

        10.3. Market Value Forecast, by End-user, 2017–2031

            10.3.1. Hospitals

            10.3.2. Sub-acute Facilities

            10.3.3. Home Care

            10.3.4. Others

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Therapy

            10.5.2. By End-user

            10.5.3. By Country/Sub-region

    11. Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Therapy, 2017–2031

            11.2.1. Oxygen Therapy

                11.2.1.1. Nasal Cannula

                11.2.1.2. Continuous Positive Airway Pressure (CPAP)

                11.2.1.3. Ventilator

            11.2.2. Surfactant Therapy

            11.2.3. Others

        11.3. Market Value Forecast, by End-user, 2017–2031

            11.3.1. Hospitals

            11.3.2. Sub-acute Facilities

            11.3.3. Home Care

            11.3.4. Others

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Therapy

            11.5.2. By End-user

            11.5.3. By Country/Sub-region

    12. Latin America Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Therapy, 2017–2031

            12.2.1. Oxygen Therapy

                12.2.1.1. Nasal Cannula

                12.2.1.2. Continuous Positive Airway Pressure (CPAP)

                12.2.1.3. Ventilator

            12.2.2. Surfactant Therapy

            12.2.3. Others

        12.3. Market Value Forecast, by End-user, 2017–2031

            12.3.1. Hospitals

            12.3.2. Sub-acute Facilities

            12.3.3. Home Care

            12.3.4. Others

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Therapy

            12.5.2. By End-user

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Therapy, 2017–2031

            13.2.1. Oxygen Therapy

                13.2.1.1. Nasal Cannula

                13.2.1.2. Continuous Positive Airway Pressure (CPAP)

                13.2.1.3. Ventilator

            13.2.2. Surfactant Therapy

            13.2.3. Others

        13.3. Market Value Forecast, by End-user, 2017–2031

            13.3.1. Hospitals

            13.3.2. Sub-acute Facilities

            13.3.3. Home Care

            13.3.4. Others

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Therapy

            13.5.2. By End-user

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Medtronic

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. SWOT Analysis

                14.3.1.5. Strategic Overview

            14.3.2. Drägerwerk AG & Co. KGaA

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. SWOT Analysis

                14.3.2.5. Strategic Overview

            14.3.3. GE HealthCare

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. SWOT Analysis

                14.3.3.5. Strategic Overview

            14.3.4. Fisher & Paykel

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. SWOT Analysis

                14.3.4.5. Strategic Overview

            14.3.5. Philips Healthcare

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. SWOT Analysis

                14.3.5.5. Strategic Overview

            14.3.6. Smiths Medical (ICU Medical, Inc.)

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. SWOT Analysis

                14.3.6.5. Strategic Overview

            1.3.5. IBIO, INC.

                14.3.6.6. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.7. Product Portfolio

                14.3.6.8. Financial Overview

                14.3.6.9. SWOT Analysis

                14.3.6.10. Strategic Overview

            14.3.7. Windtree Therapeutics Inc.

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. SWOT Analysis

                14.3.7.5. Strategic Overview

            14.3.8. Synthetic Biologics

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. SWOT Analysis

                14.3.8.5. Strategic Overview

            14.3.9. Synairgen

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Product Portfolio

                14.3.9.3. Financial Overview

                14.3.9.4. SWOT Analysis

                14.3.9.5. Strategic Overview

            14.3.10. Other Prominent Players

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Product Portfolio

                14.3.10.3. Financial Overview

                14.3.10.4. SWOT Analysis

                14.3.10.5. Strategic Overview

    List of Tables

    Table 01: Global Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031

    Table 02: Global Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 03: Global Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 04: North America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031

    Table 05: North America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 06: North America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031

    Table 08: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 09: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031

    Table 11: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 12: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031

    Table 14: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 15: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 16: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Therapy, 2017–2031

    Table 17: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 18: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    List of Figures

    Figure 01: Global Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031

    Figure 03: Global Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031

    Figure 04: Global Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 05: Global Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 06: Global Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Region, 2022 and 2031

    Figure 07: Global Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Region, 2023–2031

    Figure 08: North America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 09: North America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031

    Figure 10: North America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031

    Figure 11: North America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 12: North America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 13: North America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country, 2022 and 2031

    Figure 14: North America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country, 2023–2031

    Figure 15: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 16: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031

    Figure 17: Europe Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031

    Figure 18: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 19: Europe Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 20: Europe Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 21: Europe Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 22: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 23: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031

    Figure 24: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031

    Figure 25: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 26: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 27: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 28: Asia Pacific Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 29: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 30: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031

    Figure 31: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031

    Figure 32: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 33: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 34: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 35: Latin America Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 36: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 37: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Therapy, 2022 and 2031

    Figure 38: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Therapy, 2023–2031

    Figure 39: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 40: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by End-user, 2023–2031

    Figure 41: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 42: Middle East & Africa Neonatal Respiratory Distress Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 43: Global Neonatal Respiratory Distress Syndrome Treatment Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved